Literature DB >> 29747820

Gangliosides and Autoimmune Peripheral Nerve Diseases.

John A Goodfellow1, Hugh J Willison2.   

Abstract

A wide range of neuroimmunological diseases, referred to as autoimmune neuropathies, affect the peripheral nervous systems (PNS). The PNS is structurally diverse with complex anatomical compartments enriched in many different myelin and neuronal glycolipids, notably gangliosides. Autoimmune neuropathies are a proportion of autoimmune neuropathies mediated by autoimmune attack due to antibodies reactive with these compartmentally localized gangliosides. Antiganglioside antibodies are principally associated with the acute paralytic disease, Guillain-Barré syndrome, and are also found in several chronic autoimmune neuropathy syndromes. These antibodies may arise spontaneously from the natural autoantibody repertoire, or be induced by infections that share structurally similar glycans to gangliosides, an immunological process often referred to as molecular mimicry. The principal infection exhibiting this structural similarity is Campylobacter jejuni, which displays mimics of GM1, GD1a, GT1a, and other gangliosides on its surface lipo-oligosaccharide. Autoantibodies thus induced bind glycan epitopes on peripheral nerve gangliosides where they activate complement and recruit macrophages, causing structural and functional disorganization of nerve conduction. Chronic autoimmune neuropathies are also associated with naturally arising IgM antibodies directed against ganglioside epitopes present on disialylated gangliosides, that induce a sensory neuropathy, and on GM1, that induce a motor neuropathy. In a third syndrome, the so-called "anti-MAG" neuropathy, the antibodies bind a sulfated glucuronic acid epitope present on myelin-associated glycoprotein and the glycolipid sulfated glucuronyl paragloboside. This review will describe the immunological, pathological, and clinical features of these disorders in the context of our broader knowledge of the ganglioside glycobiology of the peripheral nervous system.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Guillain–Barré syndrome; autoantibodies; gangliosides; glycolipids; peripheral nerve; peripheral neuropathy

Mesh:

Substances:

Year:  2018        PMID: 29747820     DOI: 10.1016/bs.pmbts.2017.12.010

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  5 in total

1.  Role of 1-Deoxysphingolipids in docetaxel neurotoxicity.

Authors:  Katrin A Becker; Anne-Kathrin Uerschels; Laura Goins; Suzanne Doolen; Kristen J McQuerry; Jacek Bielawski; Ulrich Sure; Erhard Bieberich; Bradley K Taylor; Erich Gulbins; Stefka D Spassieva
Journal:  J Neurochem       Date:  2020-03-13       Impact factor: 5.372

2.  The impact of the glycan headgroup on the nanoscopic segregation of gangliosides.

Authors:  Maria J Sarmento; Michael C Owen; Joana C Ricardo; Barbora Chmelová; David Davidović; Ilya Mikhalyov; Natalia Gretskaya; Martin Hof; Mariana Amaro; Robert Vácha; Radek Šachl
Journal:  Biophys J       Date:  2021-11-17       Impact factor: 4.033

3.  An incomplete form of anti-ganglioside antibody-positive Miller Fisher syndrome after an Epstein-Barr virus infection: A case report.

Authors:  Le Chang; Jing Xiong; Yuying Xue; Jie Wang; Xurong Zhu; Xuejiao Zheng; Xiaoyu Gao; YuE Yan; Jiaduo Hao; Hehuan Zhao; Zhengli Di
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 4.  Glycosphingolipids and Infection. Potential New Therapeutic Avenues.

Authors:  Johannes M F G Aerts; M Artola; M van Eijk; M J Ferraz; R G Boot
Journal:  Front Cell Dev Biol       Date:  2019-12-06

5.  Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.

Authors:  Shaoyong Wu; Xiaohui Bai; Caixia Guo; Zhimei Huang; Handong Ouyang; Jingxiu Huang; Weian Zeng
Journal:  BMC Cancer       Date:  2021-11-02       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.